Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First

With a Phase II study stopped for efficacy in bleeding reduction, Anthos hopes to bring abelacimab, a dual Factor XI/XIa inhibitor to market to prevent strokes in a-fib patients and to treat cancer patients with thrombosis.